Simioni, S., Cavassini, M., Annoni, J.-M., Metral, M., Iglesias, K., Rimbault Abraham, A., Jilek, S., Calmy, A., Muller, H., Fayet-Mello, A., Giacobini, E., Hirschel, B., Du Pasquier, R. A.

Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]

Sierra, Saleta, Ramos, Maria C., Molina, Pilar, Esteo, Cynthia, Vázquez, Jose Antonio, Burgos, Javier S.

There is growing evidence to support the hypothesis that statins may act as neuroprotectants in several neuropathological conditions, including Alzheimer’s disease. The mechanisms for neuroprotection are only partially understood, however, and pleiotropic phenomena could be involved. We have made a comparative study of 9 statins (lovastatin, mevastatin, pravastatin, simvastatin, cerivastatin, atorvastatin, fluvastatin, pitavastatin, and rosuvastatin), […]

Sešok, Sanja, Bolle, Nika, Kobal, Jan, Bucik, Valentin, Vodušek, David B.

Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]

Sakurai, Hirofumi, Hanyu, Haruo, Sato, Tomohiko, Kume, Kazumasa, Hirao, Kentaro, Kanetaka, Hidekazu, Iwamoto, Toshihiko

Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, on cognition and regional cerebral blood flow (rCBF) in elderly patients with AD and cerebrovascular disease (CVD).; Methods: A […]

Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique

Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease (AD).; Methods: Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study-Activities of […]

Emre, Murat, Poewe, Werner, De Deyn, Peter Paul, Barone, Paolo, Kulisevsky, Jaime, Pourcher, Emmanuelle, van Laar, Teus, Storch, Alexander, Micheli, Federico, Burn, David, Durif, Frank, Pahwa, Rajesh, Callegari, Francesca, Tenenbaum, Nadia, Strohmaier, Christine

Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]

Choi, Seong Hye, Park, Kyung Won, Na, Duk L., Han, Hyun Jeong, Kim, Eun-Joo, Shim, Yong S., Lee, Jae-Hong, The EXPECT Study Group,

Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]

Burstein, Aaron H, Grimes, Imogene, Galasko, Douglas R, Aisen, Paul S, Sabbagh, Marwan, Mjalli, Adnan MM

Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]

Beking, Kristopher, Vieira, Amandio

Objective: Dietary flavonoids and their metabolites may have neuroprotective effects against age-associated neurodegenerative disorders such as Alzheimer’s and related dementias (dementia). There is a lack of population studies, however, on correlations between flavonoid intake and dementia. The main objective of the present study was to analyse such a relationship at a large-scale population level.; Design: […]